Mr. Hastings was appointed Chief Executive Officer of Nkarta in February 2018. Mr. Hastings was recently the Chairman and CEO of OncoMed Pharmaceuticals. Prior to joining OncoMed in 2006, Mr. Hastings was President and Chief Executive Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President, Genzyme Therapeutics. Mr. Hastings also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche.
He is currently Lead Independent Director of Pacira Biosciences, Inc., and Director at ViaCyte. He also serves as Chair of the Biotechnology Innovation Organization (BIO). Mr. Hastings was recently the Chairman of the Board of Proteon Therapeutics, was on the Board of Directors of Relypsa, Inc. (acquired by Galenica), was Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2010) and served on the board of ViaCell (sold to Perkin-Elmer in 2007).
Mr. Hastings received a Bachelor of Science degree in pharmacy from the University of Rhode Island.
What is Paul J. Hastings' net worth?
The estimated net worth of Paul J. Hastings is at least $2.68 million as of January 16th, 2024. Mr. Hastings owns 390,507 shares of Nkarta stock worth more than $2,682,783 as of April 26th. This net worth estimate does not reflect any other investments that Mr. Hastings may own. Additionally, Mr. Hastings receives a salary of $938,410.00 as CEO at Nkarta. Learn More about Paul J. Hastings' net worth.
How old is Paul J. Hastings?
What is Paul J. Hastings' salary?
How do I contact Paul J. Hastings?
Has Paul J. Hastings been buying or selling shares of Nkarta?
Paul J. Hastings has not been actively trading shares of Nkarta during the last ninety days. Most recently, Paul J. Hastings sold 9,697 shares of the business's stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $8.74, for a transaction totalling $84,751.78. Following the completion of the sale, the chief executive officer now directly owns 390,507 shares of the company's stock, valued at $3,413,031.18. Learn More on Paul J. Hastings' trading history.
Who are Nkarta's active insiders?
Are insiders buying or selling shares of Nkarta?
During the last year, Nkarta insiders bought shares 1 times. They purchased a total of 2,000,000 shares worth more than $20,000,000.00. During the last year, insiders at the sold shares 6 times. They sold a total of 20,866 shares worth more than $178,341.54. The most recent insider tranaction occured on March, 27th when Director Simeon George bought 2,000,000 shares worth more than $20,000,000.00. Insiders at Nkarta own 5.6% of the company.
Learn More about insider trades at Nkarta. Information on this page was last updated on 3/27/2024.
